allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Company profile
Ticker
ALLO
Exchange
Website
CEO
David D. Chang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ALLO stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
10 Jun 24
8-K
Entry into a Material Definitive Agreement
31 May 24
8-K
Other Events
14 May 24
424B5
Prospectus supplement for primary offering
14 May 24
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
13 May 24
EFFECT
Notice of effectiveness
26 Apr 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
Transcripts
ALLO
Earnings call transcript
2024 Q1
13 May 24
ALLO
Earnings call transcript
2023 Q4
14 Mar 24
ALLO
Earnings call transcript
2023 Q3
2 Nov 23
ALLO
Earnings call transcript
2023 Q2
2 Aug 23
ALLO
Earnings call transcript
2023 Q2
2 Aug 23
ALLO
Earnings call transcript
2023 Q1
3 May 23
ALLO
Earnings call transcript
2022 Q4
28 Feb 23
ALLO
Earnings call transcript
2022 Q3
3 Nov 22
ALLO
Earnings call transcript
2022 Q2
10 Aug 22
ALLO
Earnings call transcript
2022 Q1
5 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 61.33 mm | 61.33 mm | 61.33 mm | 61.33 mm | 61.33 mm | 61.33 mm |
Cash burn (monthly) | 10.71 mm | 4.91 mm | 23.17 mm | 24.85 mm | 18.63 mm | 18.92 mm |
Cash used (since last report) | 41.40 mm | 18.98 mm | 89.59 mm | 96.08 mm | 72.05 mm | 73.15 mm |
Cash remaining | 19.93 mm | 42.35 mm | -28.26 mm | -34.75 mm | -10.72 mm | -11.82 mm |
Runway (months of cash) | 1.9 | 8.6 | -1.2 | -1.4 | -0.6 | -0.6 |
Institutional ownership, Q1 2024
19.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 52 |
Opened positions | 9 |
Closed positions | 80 |
Increased positions | 12 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 22.97 bn |
Total shares | 41.34 mm |
Total puts | 30.70 k |
Total calls | 94.80 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
PFE Pfizer | 22.03 mm | $103.33 mm |
Seaview Trust | 7.04 mm | $105.05 mm |
Belldegrun Arie | 4.71 mm | $0.00 |
Vida Ventures Advisors | 1.80 mm | $8.04 bn |
Chang David D | 1.20 mm | $0.00 |
GILD Gilead Sciences | 1.16 mm | $37.69 mm |
Nordea Investment Management Ab | 742.11 k | $3.38 bn |
TD Asset Management | 437.44 k | $1.96 bn |
Mirae Asset Global Investments | 361.91 k | $1.77 bn |
BK Bank Of New York Mellon | 300.55 k | $1.34 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Jun 24 | Messemer Deborah M. | Common Stock | Sell | Dispose S | No | Yes | 2.2793 | 18,641 | 42.49 k | 166,765 |
5 Jun 24 | Messemer Deborah M. | Common Stock | Grant | Acquire A | No | No | 0 | 122,950 | 0.00 | 185,406 |
5 Jun 24 | Joshua A Kazam | Stock Option Common Stock | Grant | Acquire A | No | No | 2.44 | 191,082 | 466.24 k | 191,082 |
5 Jun 24 | Witte Owen N. | Stock Option Common Stock | Grant | Acquire A | No | No | 2.44 | 191,082 | 466.24 k | 191,082 |
5 Jun 24 | Humer Franz B | Common Stock | Grant | Acquire A | No | No | 0 | 61,475 | 0.00 | 316,728 |
5 Jun 24 | Humer Franz B | Stock Option Common Stock | Grant | Acquire A | No | No | 2.44 | 95,541 | 233.12 k | 95,541 |
News
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
19 Jul 24
Allogene Therapeutics Initiates Phase 2 Trial Investigating Cemacabtagene Ansegedleucel As Part Of First Line Treatment For Patients With Large B-Cell Lymphoma Likely to Relapse
20 Jun 24
Analyst Ratings For Allogene Therapeutics
31 May 24
Piper Sandler Initiates Coverage On Allogene Therapeutics with Overweight Rating, Announces Price Target of $11
31 May 24
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
21 May 24
Press releases
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
20 Jun 24
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
23 May 24
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
13 May 24
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
13 May 24
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
6 May 24